Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma. The tyrosine kinase inhibitors, crizotinib, lorlatinib, and entrectinib, have demonstrated favorable efficacy in treating ROS...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li, Guozhong Jiang
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2020-11-01
Цуврал:	Molecular Oncology
Нөхцлүүд:	crizotinib gene fusion next‐generation sequencing non‐small‐cell lung cancer ROS1
Онлайн хандалт:	https://doi.org/10.1002/1878-0261.12789
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!